Rune Labs appoints former Tempus executive as CEO — commercial growth phase for StrivePD Parkinson's wearable monitoring
Summary
Rune Labs appointed a new CEO with a Tempus (AI oncology data company) background in late 2025, signaling a deliberate commercial growth phase following FDA clearance of their StrivePD platform and establishment of clinical partnerships with Medtronic and Abbott for DBS programming optimization. StrivePD uses Apple Watch movement data with machine learning to generate objective Parkinson's motor metrics — replacing subjective patient diaries with continuous objective monitoring of dyskinesia, tremor, and bradykinesia. The Tempus executive hire brings AI health data commercialization expertise from the company that successfully scaled AI diagnostics across oncology to a new application in Parkinson's motor monitoring.
Why it matters
Rune Labs hiring a Tempus executive signals they are building the same AI health data commercial model that Tempus used in oncology — partnering with device manufacturers, healthcare systems, and pharmaceutical companies to provide objective biomarker data that improves clinical decisions and drug development. The DBS programming optimization partnership with both Medtronic and Abbott simultaneously is particularly notable — both competitors trust Rune to provide neutral objective motor data rather than favoring either company's stimulator.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial